Sofosbuvir and risk of estimated glomerular filtration rate decline or end-stage renal disease in patients with renal impairment.
Mark S SulkowskiLaura E TelepMassimo ColomboFrancois DurandK Rajender ReddyEric LawitzMarc BourlièreNelson CheinquerStacey ScherbakovskyLiyun NiLindsey ForceHeribert RamrothAnuj GaggarAnand P ChokkalingamMeghan E SisePublished in: Alimentary pharmacology & therapeutics (2022)
Clinical trial participants with CKD did not experience worsening eGFR during sofosbuvir-based treatment, and sofosbuvir was not associated with an increased risk of ESRD in patients with CKD in a nationally-representative administrative claims database.
Keyphrases
- end stage renal disease
- chronic kidney disease
- hepatitis c virus
- hepatitis c virus infection
- clinical trial
- peritoneal dialysis
- small cell lung cancer
- epidermal growth factor receptor
- health insurance
- emergency department
- open label
- study protocol
- randomized controlled trial
- double blind
- phase ii
- adverse drug
- replacement therapy
- electronic health record